Multipathogen Adoptive Immunotherapy For Post-transplant Virus-associated Diseases
Funder
National Health and Medical Research Council
Funding Amount
$1,074,188.00
Summary
This project is aiming to develop an “off-the-shelf” killer T cell therapy for transplant patients and patients with virus-associated malignancies. This therapy is based on a novel technology developed by our group which allows rapid expansion of killer T cells directed against multiple viruses.
Mechanisms Of Regulatory T Cell Induction By Soluble Immunomodulatory Molecules
Funder
National Health and Medical Research Council
Funding Amount
$729,414.00
Summary
The purpose of this work is to identify how a select population of cells (T regulatory cells) function to prevent or dampen down the sometimes-harmful effects of the immune system. Understanding how these cells function may have broad implications for general immune regulation.
Elucidating The Mechanism Of IL-2 Cytokine/antibody Mediated Transplantation Tolerance
Funder
National Health and Medical Research Council
Funding Amount
$624,429.00
Summary
Organ transplantation is a life-saving treatment for end-stage organ failure. However, patients must take immunosuppressive drugs to prevent rejection, a lifetime of which increases the risk of infection and cancer. An alternative to drugs is to manipulate the immune system from within. We discovered a way to boost the immune ‘regulators’ so that they stifle the graft-destroying response. We are optimising this approach with the aim of transplanting organs without long-term immunosuppression.
Combining Immune Monitoring And Immunotherapy To Tackle Cytomegalovirus Infections In Solid Organ Transplant Patients
Funder
National Health and Medical Research Council
Funding Amount
$801,416.00
Summary
Clinical management of infectious complications in kidney and heart/lung transplant patients remains significant challenge. Although prophylactic/pre-emptive treatment with antiviral drugs have shown dramatic improvements in the control of these infections, long-term treatment with these drugs is associated with significant toxicity, the appearance of drug-resistant virus isolates and significant health cost. In this proposal we will develop novel strategies to identify high risk patients and tr ....Clinical management of infectious complications in kidney and heart/lung transplant patients remains significant challenge. Although prophylactic/pre-emptive treatment with antiviral drugs have shown dramatic improvements in the control of these infections, long-term treatment with these drugs is associated with significant toxicity, the appearance of drug-resistant virus isolates and significant health cost. In this proposal we will develop novel strategies to identify high risk patients and treat these patients with killer T cells.Read moreRead less
Cytokine Responses Within The GI Tract Dictate T Cell Fate And Transplant Outcome
Funder
National Health and Medical Research Council
Funding Amount
$1,479,579.00
Summary
Over 10,000 persons per year in Australia are diagnosed with a blood cancer, accounting for 10% of cancer deaths. Stem cell transplantation remains curative therapy for these diseases but is limited by a process known as graft-versus-host disease (GVHD), responsible for mortality in up to 50% of patients. This project will focus on immune responses within the colon as the critical event initiating lethal GVHD, defining new treatments that will be translated to improve transplant outcomes.
Clinical Implications Of Trans-kingdom Microbial Interactions In The Transplanted Lung
Funder
National Health and Medical Research Council
Funding Amount
$631,909.00
Summary
Lung transplantation is a critical requirement for people with severe lung diseases. The lung is constantly exposed to bugs and viruses, which reside in the airways, and can be both beneficial or detrimental for lung health. This interaction between the immune system and these bugs can influence the health and longevity of the lung transplant. We aim to discover how we could target these interactions to improve the long-term success of lung transplantation.
Failure Of Donor Antigen Presentation Promotes IL-17 Dependant Chronic GVHD
Funder
National Health and Medical Research Council
Funding Amount
$585,860.00
Summary
Bone marrow transplantation (BMT) is the most effective treatment for a number of haematological conditions, especially leukemia. Graft versus host disease (GVHD) is a complication of BMT and results in the death of up to 50% of transplant recipients. GVHD occurs when the newly transplanted immune system recognizes the recipient as foreign and mounts and immune reponse against the patients tissues. These studies will focus on identifying and understanding the function of the immune cells which d ....Bone marrow transplantation (BMT) is the most effective treatment for a number of haematological conditions, especially leukemia. Graft versus host disease (GVHD) is a complication of BMT and results in the death of up to 50% of transplant recipients. GVHD occurs when the newly transplanted immune system recognizes the recipient as foreign and mounts and immune reponse against the patients tissues. These studies will focus on identifying and understanding the function of the immune cells which drive GVHD.Read moreRead less
The Role Of Gut Resident Antigen Presenting Cells In Graft-versus-host Disease
Funder
National Health and Medical Research Council
Funding Amount
$409,909.00
Summary
Allogeneic stem cell transplantation (SCT) is curative therapy for most blood cancers, since donor immune cells can eliminate cancers which cannot be eradicated by chemotherapy. However these donor cells can also attack normal cells in a process known as graft-versus-host disease. This research aims to understand how immune responses are induced after SCT to promote cancer eradication, whilst inhibiting GVHD, thus curing more patients of cancer and maintaining a normal quality of life.